TABLE 3.
Combined (N = 147) | Before (N = 55) | During/after (N = 92) | p‐value | |
---|---|---|---|---|
In‐hospital outcomes | ||||
Death | 44% (64) | 29%16 | 52% (48) | <.01 |
Life‐threatening or severe bleeding | 13%19 | 7%4 | 16%15 | .11 |
Number of red blood cell transfusions | 2 [5;14] | 2 [5;12] | 2 [5;14] | .58 |
Device‐related complications | 35% (52) | 29%16 | 39% (36) | .29 |
Access‐site bleeding | 12%17 | 11%6 | 12%11 | 1 |
Limb ischemia | 15%21 | 17%9 | 19%17 | .46 |
Need for endovascular intervention | 7%10 | 7%4 | 7%1 | 1 |
Aortic injury | 1%1 | 0% (0) | 1%1 | 1 |
Left ventricular perforation | 0% (0) | 0% (0) | 0% (0) | NA |
Sepsis | 30% (42) | 31%17 | 29%25 | .85 |
Acute kidney injurya | 53% (70) | 38%18 | 61% (52) | .02 |
Need for renal replacement therapy | 27% (38) | 21%11 | 31% (27) | .23 |
Escalation therapyb | 19% (27) | 17%9 | 20%18 | .68 |
LVEF at discharge, % | 33 [25;42] | 33 [25;42] | 33 [25;45] | .62 |
Note: In‐hospital outcomes are reported as n (%) or median (interquartile range) as appropriate.
Abbreviation: LVEF, left‐ventricular ejection fraction.
Defined as a serum creatinine increase ≥0.3 mg/dl from baseline.
Defined as the need for extracorporeal membrane oxygenation, other left ventricular assist device implantation or heart transplant.